Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Semiconductor ETF (SOXX) vs Tenet Healthcare Corporation (THC) Price & Performance

iShares Semiconductor ETFTrade
Tenet Healthcare CorporationTrade

Price performance (Past 24H)

Key statistics

iShares Semiconductor ETF vs Tenet Healthcare Corporation — how do they compare? iShares Semiconductor ETF trades at $560 (market cap $48.19B), while Tenet Healthcare Corporation trades at $263.45 (market cap $20.98B). The key difference: iShares Semiconductor ETF is far larger — about 2.3× Tenet Healthcare Corporation's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Semiconductor ETF for 46 Days and Tenet Healthcare Corporation for 15 Days on average.

SOXXTHC
Market Cap
$48.19B$20.98B
Volume
10,257,578428,008
Sector
Sector/ThematicHealth
52-Week High
$655.01$280.77
52-Week Low
$268.10$161.37
Typical Hold Time
46 Days15 Days
Enterprise Value
—$32.06B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Semiconductor ETF

SOXX trades at $559.67, down 3.99% on the day but maintains a bullish technical outlook with strong moving average signals. The semiconductor ETF benefits from AI-driven demand, with Bank of America projecting the global chip market could nearly double by 2030. Recent news highlights strong September performance and ongoing institutional interest, though Michael Burry's expanded short position signals some bearish sentiment.

The outlook remains positive given structural AI growth catalysts, but investors face valuation concerns with SOXX trading at a P/E premium versus broader markets. Key risks include concentration in top holdings and potential AI development slowdowns. Wall Street maintains generally bullish ratings based on earnings growth potential.

Tenet Healthcare Corporation

Tenet Healthcare (THC) trades at $265.42, up 2.15% today, with a bullish technical signal from moving averages and strong support near $257. The company shows robust fundamentals, including a 53.31% ROE and consistent earnings beats, with Q3 2026 results due October 29. Revenue growth is supported by higher revenue per case despite softer surgical volumes, as noted by Zacks on September 24, 2026.

The outlook is positive, with an 81.25% analyst buy rating and a $283.36 consensus price target implying ~7% upside. Risks include sustainability of capital returns amid growth investments and potential volume pressures, but solid cash flow and valuation metrics like a 10.07 P/E suggest room for appreciation if execution continues.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SOXX
40% Buy60% Sell
Avg holding period · 46 Days
THC

No sentiment data available yet.

Top news

Latest headlines on both assets

About iShares Semiconductor ETF

SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.

Read more on SOXX →

About Tenet Healthcare Corporation

Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.

Read more on THC →